Around 90 percent of all pharmaceutical drugs belong to heterocycles.  The molecular structure contains at least one ring in addition to carbon atoms it also contains nitrogen or sulfur. The tranquilizer diazepam is also included in heterocyclic compounds such as cholesterol lowering agents,  atorvastatin or sildenafil; agent for treating erectile dysfunction. In the search for… Read More A New Synthesis Method is likely to revolutionize the Search for New Drugs

It becomes clearer every day that human civilisation has an enormous impact on the global environment and this impact is rarely a positive one. Significant changes are needed in order to slow down climate change, prevent pollution and sustain dwindling natural resources. This need is particularly clear in the chemical industry, which is why more… Read More The Golden Age of Green Chemistry

’Green’ chemistry; renewable chemicals derived from bio-based feedstocks using environmentally friendly production technologies, has gone global. BCC Research estimates in its new report entitled, ‘Global Markets for Renewable Chemicals Manufacturing (ENV032A)’, the global chemical industry will grow to over US$1.5 trillion/y when bio-based and renewable products replace existing products and provide new revenue sources to… Read More BCC Research: Green chemistry markets growing

While drug developers during the coming year will continue their efforts to meet the growing demand for innovative new medicines, they must also significantly scale up their level of process improvements if they are to reduce the time and cost required to bring new drugs to market, according to the Tufts Center for the Study… Read More Drug Developers Are Working to Boost R&D Productivity, But Need to Do More to Achieve Large-Scale Improvements

The pharmaceutical sector is one of the most innovative industries in Canada. It is composed of companies developing and manufacturing innovative medicines and generic pharmaceuticals, as well as over the counter drug products. The sector is made up of a number of sub-sectors that service different market segments, these include brand-name pharmaceuticals companies, generic drug… Read More Canada’s pharmaceutical sector

Most pharmaceutical drugs consist of tiny molecules, which target a class of proteins found on the surfaces of cell membranes. Studying these subtle interactions is essential for the design of effective drugs, but the task is extremely challenging. Now, Nongjian (NJ) Tao and his colleagues at Arizona State University’s Biodesign Institute describe a new method… Read More Drug Design Revolutionized by Small Molecules

Accelerating Drugs to Market – Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market Accelerating Drugs to Market Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market, presents various tools and strategies which can accelerate a drug to the market. In this report, GBI Research has studied… Read More Global Accelerating Drugs to Market 2015 Forecast by Market Research Store

Scientists at the University of Bath have identified that a combination of two existing licensed drugs could be used as a potential new treatment for depression. Current antidepressants, called SSRIs, increase the amount of serotonin in the brain although the exact mechanism by which they work is still unclear. However around 30-50 per cent of… Read More Drug combination highlights potential new depression treatment

Leaves of the European chestnut tree contain ingredients with the power to disarm dangerous staph bacteria without boosting its drug resistance, scientists have found. PLOS ONE is publishing the study of a chestnut leaf extract, rich in ursene and oleanene derivatives, that blocks Staphlococcus aureus virulence and pathogenesis without detectable resistance. The use of chestnut… Read More European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

Sales at Rs 6,157 crore were also about 16.5 per cent lower than expected. Although net profit at Rs 892 crore was helped by MAT credit of Rs 600 crore, it was still about 50 per cent lower than anticipated by analysts. Post completion of the Ranbaxy acquisition, this is the first quarter where Sun’s… Read More Ranbaxy: A new challenge for Sun Pharma